---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-108722"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:20:42.192708+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BiomX Q3 net loss $9.2M; cash $8.1M; FDA feedback for BX011 and BX004 positive

## Summary
- Net loss of $9.2M in Q3 2025 vs net income of $9.6M in Q3 2024 due to warrant fair value changes.
- Cash and restricted cash $8.1M as of Sep 30, 2025, from $18M at Dec 31, 2024; runway into Q1 2026.
- R&D expenses $6.1M, G&A $2.4M; net cash used in operations $22.0M for nine months vs $30.7M in 2024.
- FDA provided positive feedback on BX011 clinical pathway for S. aureus diabetic foot infections; Phase 2a planned.
- BX004 clinical hold feedback imminent; Phase 2b topline results expected Q1 2026; FDA outlined potential Phase 3 pathways.

## SEC filing metadata
- accession: 0001213900-25-108722
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390025108722/0001213900-25-108722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390025108722/ea0265281-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-108722
- JSON: https://secwatch.observer/filing/0001213900-25-108722.json
- Plain text: https://secwatch.observer/filing/0001213900-25-108722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.